Esperion's drug lowers blood fat in mid-stage study
Sept 3 (Reuters) - Esperion Therapeutics Inc said its drug reduced levels of bad blood fat in a mid-stage trial among patients with high levels of cholesterol, when added to a standard of care treatment.
The company said the drug lowered bad cholesterol by an additional 22 percent, compared with a placebo, after eight weeks of use with another drug atorvastatin. The placebo group showed no additional reduction in cholesterol.
The drug was well tolerated and no serious adverse events were reported, Esperion said.
- Cortege departs to take Mandela's body to lie in state |
- U.S. Mega Millions lottery up to $344 million, fourth biggest in its history
- Uruguay becomes first country to legalize marijuana trade
- UPDATE 2-U.S. Mega Millions lottery up to $400 million, 2nd-biggest ever
- U.S. budget deal could usher in new era of cooperation